A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs ACE 083 (Primary)
- Indications Facioscapulohumeral muscular dystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Acceleron Pharma
- 03 Aug 2017 According to an Acceleron Pharma media release, the company expects to present results from all dose-escalation cohorts in part 1 in 2018.
- 06 Jan 2017 According to an Acceleron Pharma media release, the company expects to present top-line results from the open label, dose-escalation part in late 2017 and initiate the randomized, double-blind, placebo-controlled stage of the study in 2018.
- 29 Nov 2016 Status changed from not yet recruiting to recruiting.